share_log

Femasys | 10-Q: Q3 2024 Earnings Report

Femasys | 10-Q: Q3 2024 Earnings Report

Femasys | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/12 09:34

Moomoo AI 已提取核心訊息

Femasys Inc. reported Q3 2024 revenue of $554,908, up 127% YoY, driven by initial commercial sales of FemaSeed infertility treatment and increased FemVue sales. The quarter marked the first U.S. and international sales of FemaSeed following FDA clearance in September 2023, with strategic distribution partnerships established in Spain expected to generate over $1.3 million in the next year.Operating expenses increased 29.3% to $5.48 million, primarily due to a $1.5 million rise in sales and marketing costs as the company built out its commercial team. R&D expenses grew 11.1% to $2.3 million focused on advancing the FemBloc permanent birth control pivotal trial. Net loss widened to $5.41 million from $4.0 million last year.The company ended Q3 with $7.61 million in cash and cash equivalents, which management expects will fund operations into July 2025. However, Femasys indicated substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is exploring various funding options while advancing commercialization of FemaSeed and clinical development of FemBloc.
Femasys Inc. reported Q3 2024 revenue of $554,908, up 127% YoY, driven by initial commercial sales of FemaSeed infertility treatment and increased FemVue sales. The quarter marked the first U.S. and international sales of FemaSeed following FDA clearance in September 2023, with strategic distribution partnerships established in Spain expected to generate over $1.3 million in the next year.Operating expenses increased 29.3% to $5.48 million, primarily due to a $1.5 million rise in sales and marketing costs as the company built out its commercial team. R&D expenses grew 11.1% to $2.3 million focused on advancing the FemBloc permanent birth control pivotal trial. Net loss widened to $5.41 million from $4.0 million last year.The company ended Q3 with $7.61 million in cash and cash equivalents, which management expects will fund operations into July 2025. However, Femasys indicated substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is exploring various funding options while advancing commercialization of FemaSeed and clinical development of FemBloc.
Femasys Inc. 報告2024年第三季度營業收入爲554,908美元，同比增長127%，這主要得益於FemaSeed不孕症治療的初步商業銷售和FemVue銷售的增加。該季度標誌着在2023年9月獲得FDA批准後，FemaSeed首次在美國和國際市場的銷售，並在西班牙建立的戰略分銷合作伙伴關係預計將在明年產生超過130萬美元的收入。營業費用增長29.3%，達到548萬美元，主要由於公司擴大商業團隊而導致銷售和市場營銷成本上升150萬美元。研發費用增長11.1%，達到230萬美元，專注於推進FemBloc永久避孕的關鍵試驗。淨虧損擴大至541萬美元，而去年爲400萬美元。公司在第三季度末擁...展開全部
Femasys Inc. 報告2024年第三季度營業收入爲554,908美元，同比增長127%，這主要得益於FemaSeed不孕症治療的初步商業銷售和FemVue銷售的增加。該季度標誌着在2023年9月獲得FDA批准後，FemaSeed首次在美國和國際市場的銷售，並在西班牙建立的戰略分銷合作伙伴關係預計將在明年產生超過130萬美元的收入。營業費用增長29.3%，達到548萬美元，主要由於公司擴大商業團隊而導致銷售和市場營銷成本上升150萬美元。研發費用增長11.1%，達到230萬美元，專注於推進FemBloc永久避孕的關鍵試驗。淨虧損擴大至541萬美元，而去年爲400萬美元。公司在第三季度末擁有761萬美元的現金及現金等價物，管理層預計這將可以支持運營直到2025年7月。然而，Femasys表示對其在沒有額外融資的情況下繼續作爲一個持續經營實體的能力產生了相當大的懷疑。公司正在探索各種融資選項，同時推進FemaSeed的商業化和FemBloc的臨牀開發。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Femasys
    FEMY
    -- 1.5900
    Predictive Oncology
    POAI
    -- 1.6200
    West Pharmaceutical Services
    WST
    -- 214.730
    NexGel
    NXGL
    -- 3.530
    BioNano Genomics
    BNGO
    -- 5.7600
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！